2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 373

The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data
Abstract Number: 374

Nailfold Microangiopathy in Dermatomyositis and Systemic Sclerosis: What Is Different?
Abstract Number: 375

Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”
Abstract Number: 376

Antisynthetase Syndrome: Prevalence of Serositis in Autoantibody Subsets
Abstract Number: 377

Preliminary Validation of Rectus Femoris Muscle Ultrasound in Idiopathic Inflammatory Myopathy Patients
Abstract Number: 378

Pulmonary Hypertension in Anti-Synthetase Syndrome
Abstract Number: 379

Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
Abstract Number: 380

A New Tool to Assess Muscle Strength in Polymyositis and Dermatomyositis: Hand-Held Dynamometry
Abstract Number: 381

Muscle Endurance Deficits in Myositis Patients Despite Normal Manual Muscle Testing Scores
Abstract Number: 382

Nailfold Capillary Changes in the Adult Newly Onset-Dermatomyositis: A Prospective Cohort Study
Abstract Number: 383

Myositis Patients with Anti-U1-RNP and Anti-Ro52 Autoantibodies Are at Risk of Pericarditis, Glomerulonephritis, and Pulmonary Hypertension
Abstract Number: 384

Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
Abstract Number: 385

Sexual Dysfunction in Female Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 386

Differences in Body Composition in Myositis Patients and Healthy Controls Are Associated with Disease Activity and Duration, Inflammatory Status, Skeletal Muscle Involvement and Physical Activity
Abstract Number: 387

Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].